SOURCE: Salas Labs International, Inc.

August 31, 2010 08:00 ET

Salus Labs Announces New Name, New Business Model, New Management

LAS VEGAS, NV--(Marketwire - August 31, 2010) - Salas Labs International, Inc. (PINKSHEETS: IPEX) is pleased to announce today the company has embarked on a new business model, a change of name from IPEX, Inc. to Salas Labs International, and new leadership. After nearly two years of research, development, and testing, Salus Labs is making a major shift into the health, nutrition, and fitness markets, under the guidance of new CEO Art Wenzlaff.

The company intends to develop, produce, and market high-quality nutritional supplements and anti-aging products. Salus Labs has initially defined its target market as the over-35 age group. Generally, this population values good health, and will become loyal customers to high-quality nutrition and fitness products that produce the desired results. The company will focus on the issues of aging and the sustainment of improved long-term health and fitness.

It is expected that one or more products will be released in 2010. To date, while clinical testing of several products continues, an anti-aging product has shown rather remarkable results. Another product undergoing testing will focus on the vast number of people, world-wide, who are either directed to, or prefer to, lower body weight and/or cholesterol levels.

Art Wenzlaff, CEO, indicates, "Our company is in the right place at the right time for major contributions to the health and fitness industry. Our intention is to produce unique, one-of-a-kind products, which will create their own demand. 'Better Living Through Chemistry,' the credo of our scientific staff, is the guide post to our mission of improving the quality of life of our customers. Through the success of these products corporate growth and shareholder value will significantly improve."

Additional information will be forthcoming including initial product release, clinical test results, product development, expansion plans and initiation of the corporate web site. During the last quarter of 2010 the company intends to be operational and revenue producing.

Additional business activities

--  Salus Labs principle management team includes:

         - Art Wenzlaff, PhD, President and CEO

           Art's experience includes many years as a public school
           administrator with a strong background in organization and
           administration, compliance, grant writing, public relations,
           marketing, advertising, and media relations.  These skills play
           a significant role for the company and the products that it is
           bringing to market.

         - Curtis Wenzlaff, consultant and COB

           Curt is very experienced in creating and nurturing business
           alliances. He has successfully developed both U.S. and
           international business relationships with businesses and
           individuals who are influential in the health care industry and
           health care professionals who share similar interests.

--  Share structure at August 19, 2010:

    Common
    ------

    Auth                    75,000,000
    OS                      15,234,565
    Float                    4,921,291
    Preferred                     None

--  Corporate Headquarters expects to move to Las Vegas, NV, later this
    year. Current address is: 1802 Hampden Road, Flint, MI 48503

--  The company intends to become fully reporting as quickly as possible.

--  With respect to a symbol change, as of June 1, 2010, FINRA has adopted
    a policy of not accommodating requests for a change in the trading
    symbol until further notice.  FINRA has indicated that a new policy for
    symbol changes will be released later this year and at that time Salus
    Labs will consider the possibility.  Therefore, for the near future,
    shareholders can expect that the symbol "IPEX" will continue to be
    used.

--  The corporate web site is expected to be developed and operational by
    late September.  The company intends to keep the site current,
    transparent, and provide an effective means for communications between
    management, its shareholders, and the investment community.

--  The company's IR contact is Gary Patterson.  To insure prompt response
    the company encourages questions and comments be directed to Gary at
    ir@saluslabs.com or 714-369-2933.

About Salus Labs, International, Inc.

Salus Labs, International, Inc., a Nevada Corporation, is focused primarily on the research, development, production, and marketing of high-quality nutritional supplements and anti-aging products. It currently trades on the OTC Markets as IPEX.PK.

Notice on Forward-Looking Statements:

The matters set forth in this press release may contain forward-looking statements regarding Salas Labs and its business within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date on which they are made and Salas Labs undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Statements are subject to risks and uncertainties that may cause actual results to differ materially.

Contact Information

  • For Information Contact:
    Investor relations
    Gary Patterson
    ir@saluslabs.com
    714-369-2933